Drugs / FL-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05181865 | Jan 2022 | gastric cancer, malignant pancreatic neoplasm | Flame Biosciences | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FL-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05181865 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT05181865 ↗ |